vs
NB Bancorp, Inc.（NBBK）与RIGEL PHARMACEUTICALS INC（RIGL）财务数据对比。点击上方公司名可切换其他公司
RIGEL PHARMACEUTICALS INC的季度营收约是NB Bancorp, Inc.的1.1倍（$69.8M vs $63.4M），RIGEL PHARMACEUTICALS INC净利率更高（384.0% vs 12.2%，领先371.9%），NB Bancorp, Inc.同比增速更快（33.9% vs 21.2%），过去两年RIGEL PHARMACEUTICALS INC的营收复合增速更高（53.7% vs 22.6%）
NB Bancorp, Inc.是一家总部位于美国的银行控股公司，通过旗下全资银行子公司运营，提供全系列零售及商业银行服务，包括存款产品、消费贷款、住房抵押贷款、小微企业融资方案，主要服务纽约大都会区的个人及中小微企业客户。
Rigel制药是一家临床阶段生物技术企业，专注于研发及商业化针对自身免疫性疾病、炎症性疾病与血液疾病的靶向小分子疗法，核心市场位于美国，旗下已获批产品可治疗成人免疫性血小板减少症，致力于满足未被覆盖的临床医疗需求。
NBBK vs RIGL — 直观对比
营收规模更大
RIGL
是对方的1.1倍
$63.4M
营收增速更快
NBBK
高出12.7%
21.2%
净利率更高
RIGL
高出371.9%
12.2%
两年增速更快
RIGL
近两年复合增速
22.6%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $63.4M | $69.8M |
| 净利润 | $7.7M | $268.1M |
| 毛利率 | — | 91.5% |
| 营业利润率 | 23.5% | 33.2% |
| 净利率 | 12.2% | 384.0% |
| 营收同比 | 33.9% | 21.2% |
| 净利润同比 | -50.6% | 1769.2% |
| 每股收益（稀释后） | $0.19 | $14.11 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收NBBKRIGL
| Q4 25 | $63.4M | $69.8M | ||
| Q3 25 | $51.7M | $69.5M | ||
| Q2 25 | $51.2M | $101.7M | ||
| Q1 25 | $47.4M | $53.3M | ||
| Q4 24 | $47.3M | $57.6M | ||
| Q3 24 | $42.6M | $55.3M | ||
| Q2 24 | $41.7M | $36.8M | ||
| Q1 24 | $42.1M | $29.5M |
净利润NBBKRIGL
| Q4 25 | $7.7M | $268.1M | ||
| Q3 25 | $15.4M | $27.9M | ||
| Q2 25 | $14.6M | $59.6M | ||
| Q1 25 | $12.7M | $11.4M | ||
| Q4 24 | $15.6M | $14.3M | ||
| Q3 24 | $8.4M | $12.4M | ||
| Q2 24 | $9.5M | $-1.0M | ||
| Q1 24 | $8.7M | $-8.2M |
毛利率NBBKRIGL
| Q4 25 | — | 91.5% | ||
| Q3 25 | — | 93.2% | ||
| Q2 25 | — | 95.6% | ||
| Q1 25 | — | 91.7% | ||
| Q4 24 | — | 89.9% | ||
| Q3 24 | — | 85.5% | ||
| Q2 24 | — | 92.4% | ||
| Q1 24 | — | 93.1% |
营业利润率NBBKRIGL
| Q4 25 | 23.5% | 33.2% | ||
| Q3 25 | 38.6% | 40.9% | ||
| Q2 25 | 36.6% | 60.1% | ||
| Q1 25 | 37.1% | 23.9% | ||
| Q4 24 | 40.7% | 28.9% | ||
| Q3 24 | 36.1% | 25.4% | ||
| Q2 24 | 28.3% | 1.2% | ||
| Q1 24 | 28.8% | -23.6% |
净利率NBBKRIGL
| Q4 25 | 12.2% | 384.0% | ||
| Q3 25 | 29.7% | 40.2% | ||
| Q2 25 | 28.5% | 58.6% | ||
| Q1 25 | 26.7% | 21.5% | ||
| Q4 24 | 33.0% | 24.9% | ||
| Q3 24 | 19.7% | 22.5% | ||
| Q2 24 | 22.7% | -2.8% | ||
| Q1 24 | 20.7% | -27.9% |
每股收益（稀释后）NBBKRIGL
| Q4 25 | $0.19 | $14.11 | ||
| Q3 25 | $0.43 | $1.46 | ||
| Q2 25 | $0.39 | $3.28 | ||
| Q1 25 | $0.33 | $0.63 | ||
| Q4 24 | $0.40 | $0.82 | ||
| Q3 24 | $0.21 | $0.70 | ||
| Q2 24 | $0.24 | $-0.06 | ||
| Q1 24 | $0.22 | $-0.47 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $155.0M |
| 总债务越低越好 | — | $52.5M |
| 股东权益账面价值 | $858.9M | $391.5M |
| 总资产 | $7.0B | $513.6M |
| 负债/权益比越低杠杆越低 | — | 0.13× |
8季度趋势，按日历期对齐
现金及短期投资NBBKRIGL
| Q4 25 | — | $155.0M | ||
| Q3 25 | — | $137.1M | ||
| Q2 25 | — | $108.4M | ||
| Q1 25 | — | $77.1M | ||
| Q4 24 | — | $77.3M | ||
| Q3 24 | — | $61.1M | ||
| Q2 24 | — | $49.1M | ||
| Q1 24 | — | $49.5M |
总债务NBBKRIGL
| Q4 25 | — | $52.5M | ||
| Q3 25 | — | $60.0M | ||
| Q2 25 | — | $60.0M | ||
| Q1 25 | — | $60.0M | ||
| Q4 24 | — | $60.0M | ||
| Q3 24 | — | $60.0M | ||
| Q2 24 | — | $60.0M | ||
| Q1 24 | — | $60.0M |
股东权益NBBKRIGL
| Q4 25 | $858.9M | $391.5M | ||
| Q3 25 | $737.0M | $117.6M | ||
| Q2 25 | $737.1M | $81.9M | ||
| Q1 25 | $739.6M | $18.6M | ||
| Q4 24 | $765.2M | $3.3M | ||
| Q3 24 | $747.4M | $-14.6M | ||
| Q2 24 | $734.3M | $-29.9M | ||
| Q1 24 | $733.8M | $-31.7M |
总资产NBBKRIGL
| Q4 25 | $7.0B | $513.6M | ||
| Q3 25 | $5.4B | $242.5M | ||
| Q2 25 | $5.2B | $206.7M | ||
| Q1 25 | $5.2B | $176.0M | ||
| Q4 24 | $5.2B | $164.0M | ||
| Q3 24 | $5.0B | $139.4M | ||
| Q2 24 | $4.8B | $128.4M | ||
| Q1 24 | $4.7B | $126.5M |
负债/权益比NBBKRIGL
| Q4 25 | — | 0.13× | ||
| Q3 25 | — | 0.51× | ||
| Q2 25 | — | 0.73× | ||
| Q1 25 | — | 3.23× | ||
| Q4 24 | — | 18.25× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $60.8M | $22.0M |
| 自由现金流经营现金流 - 资本支出 | $57.4M | — |
| 自由现金流率自由现金流/营收 | 90.6% | — |
| 资本支出强度资本支出/营收 | 5.4% | — |
| 现金转化率经营现金流/净利润 | 7.89× | 0.08× |
| 过去12个月自由现金流最近4个季度 | $117.2M | — |
8季度趋势，按日历期对齐
经营现金流NBBKRIGL
| Q4 25 | $60.8M | $22.0M | ||
| Q3 25 | $24.2M | $24.0M | ||
| Q2 25 | $27.0M | $30.5M | ||
| Q1 25 | $9.9M | $-893.0K | ||
| Q4 24 | $43.2M | $14.5M | ||
| Q3 24 | $8.6M | $21.7M | ||
| Q2 24 | $24.7M | $302.0K | ||
| Q1 24 | $-11.4M | $-5.0M |
自由现金流NBBKRIGL
| Q4 25 | $57.4M | — | ||
| Q3 25 | $23.9M | — | ||
| Q2 25 | $26.1M | — | ||
| Q1 25 | $9.8M | — | ||
| Q4 24 | $41.3M | — | ||
| Q3 24 | $8.4M | — | ||
| Q2 24 | $23.8M | — | ||
| Q1 24 | $-11.7M | — |
自由现金流率NBBKRIGL
| Q4 25 | 90.6% | — | ||
| Q3 25 | 46.3% | — | ||
| Q2 25 | 51.0% | — | ||
| Q1 25 | 20.8% | — | ||
| Q4 24 | 87.2% | — | ||
| Q3 24 | 19.7% | — | ||
| Q2 24 | 57.1% | — | ||
| Q1 24 | -27.7% | — |
资本支出强度NBBKRIGL
| Q4 25 | 5.4% | — | ||
| Q3 25 | 0.6% | — | ||
| Q2 25 | 1.9% | — | ||
| Q1 25 | 0.2% | — | ||
| Q4 24 | 4.1% | — | ||
| Q3 24 | 0.5% | — | ||
| Q2 24 | 2.1% | — | ||
| Q1 24 | 0.6% | — |
现金转化率NBBKRIGL
| Q4 25 | 7.89× | 0.08× | ||
| Q3 25 | 1.58× | 0.86× | ||
| Q2 25 | 1.85× | 0.51× | ||
| Q1 25 | 0.79× | -0.08× | ||
| Q4 24 | 2.77× | 1.01× | ||
| Q3 24 | 1.03× | 1.75× | ||
| Q2 24 | 2.61× | — | ||
| Q1 24 | -1.31× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
